Upstate Group, CXR Biosciences, Cellomics, Odyssey Thera, Lexicon Genetics, Kalypsys, Scripps Research Institute, Galapagos, Celera Genomics | GenomeWeb

Upstate Partners with CXR Biosciences
to Develop Drug-Screening Tests

Upstate Group, a Serologicals subsidiary, and CXR Biosciences plan to co-develop a series of in vitro tests to aid in the early-stage drug-discovery process, the companies said last week.

Upstate Group will partner with Dundee, Scotland-based CXR to develop the drug toxicity and metabolism screens to profile compounds in various cell-based and in vitro assays, the companies said.

Financial details were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.